Management of patients with severe acute respiratory failure due to SARS-CoV-2 pneumonia with noninvasive ventilatory support outside Intensive Care Unit by Diaz De Teran, T. et al.
Vol. 112 - No. 3 MiNerVa Medica 329
O R I G I N A L  A R T I C L E
Management of patients with severe acute 
respiratory failure due to SarS-coV-2 
pneumonia with noninvasive ventilatory 
support outside intensive care Unit
Teresa diaZ de TeraN 1, Monica GONZaLeS MarTiNeZ 1, 
Paolo BaNFi 2, Giancarlo GarUTi 3, Gianluca FerraiOLi 4, Giuseppe rUSSO 4, 
Francesco caSU 4, Michela ViVareLLi 4, Monica BONFiGLiO 4, alessandro PeraZZO 5, 
cornelius BarLaSciNi 6, armando BaULeO 7, antonello NicOLiNi 5 *, Paolo SOLidOrO 8, 9
1Unit of Pulmonary Sleep disorders and Noninvasive Ventilation, Marqués de Valdecilla Hospital, Santander, 
Spain; 2Unit of rehabilitation Pulmonology, irccS don Gnocchi Foundation, Milan, italy; 3Unit of Pulmonology, 
Santa Maria Bianca Hospital, Mirandola, Modena, italy; 4cOVid respiratory intensive care Unit, General 
Hospital, Sestri Levante, italy; 5Unit of respiratory diseases, General Hospital, Sestri Levante, Genoa, italy; 6Unit 
of Hygiene and Health care Medicine, General Hospital, Sestri Levante, Genoa, italy; 7Independent Scientific 
consultant, Modena, italy; 8Unit of respiratory diseases, department cardiovascular and Thoracic diseases, città 
della Salute e della Scienza, Turin, italy; 9department of Medical Science, University of Turin, Turin, italy
*corresponding author: antonello Nicolini, Unit pf respiratory diseases, General Hospital, Via Terzi 47, Sestri Levante, Genoa, 
italy. e-mail: antonellonicolini@gmail.com
a B S T r a c T
BacKGrOUNd: cOVid-19 has high mortality rate mainly stemming from acute respiratory distress leading to respira-
tory failure (arF). aim of the study was to evaluate the management of severe arF due to cOVid-19 pneumonia using 
noninvasive ventilatory support (NiVS), studying safety and effectiveness of NiVS.
MeTHOdS: This is a retrospective, multicenter study. Primary outcomes were NiVS failure with intubation rate and hos-
pital mortality. Secondary outcomes were hospital stay and factors related to NiVS failure and mortality. These outcomes 
were compared with patients intubated and admitted to icU.
reSULTS: One hundred sixty-two patients were hospitalized because of severe respiratory failure (PaO2/FiO2 ratio 
<250). One hundred thirty-eight patients were admitted to respiratory intermediate care Unit (ricU) for a NiVS trial. 
One hundred patients were treated successfully with NiVS (74.5%); 38 failed NiVS trial (27.5%). in-hospital mortality 
was 23.18% in ricU group and 30.55% in icU group. Patients with NiVS failure were older, had a lower number of 
lymphocytes, a higher iL-6, lower PaO2, Pac O2, PaO2/FiO2 ratio, higher respiratory rate (rr) and heart rate at admis-
sion and lower PaO2, and PaO2/FiO2 ratio and higher RR after 1-6 hours. Multivariate analysis identified higher age, 
c-reactive protein as well as rr after 1-6 hours and PaO2/FiO2 ratio after 1-6 hours as an independent predictor mortality.
cONcLUSiONS: NiVS is a safe and effective strategy in the treatment of severe arF due to cOVid-19 related pneu-
monia, that reduces mortality and length of hospital stay in the carefully selected patients.
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The use and the choice of a ventilatory sup-port for acute respiratory failure (arF) due 
to SarS-coronavirus 2 (SarS-coV-2) pneu-
monia has been widely debated. due to a lack of 
established treatment protocols against the virus’ 
severest manifestations, clinicians need to rely 
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edema (ground glass) which triggered by the vi-
rus itself. Type L may deteriorate into type H. 
Here there are bilateral lung infiltrates and acute 
respiratory distress syndrome (ardS).4, 5
an early study from Wuhan including 18 pa-
tients with cOVid-19 admitted to icU suggest-
ed a significantly poor pulmonary recruitability 
and compromised hemodynamic perfusion due 
to disrupted vaso-regulation caused by vascular 
insult. Thus, the common approach of apply-
ing high levels of positive expiratory pressure 
(PeeP) may lead worse outcomes.6
in our study we aimed to evaluate the safety 
and the effectiveness of NiVS in patients with 
severe arF (PaO2/FiO2 less than 250) due to 
SarS-coV-2 pneumonia.
Materials and methods
This retrospective observational study was con-
ducted in respiratory intermediate care units 
(ricUs) of Hospital of Santander, Spain, and 
don Gnocchi Foundation Milan, italy, and cO-
Vid intensive care Unit (icU). The Local insti-
tutional review Boards approved this study as 
minimal-risk research using data collected for 
routine clinical practice. due to the nature of ret-
rospective review, the Boards waived the need 
for informed consent. Between March 14, 2020 
and May 20, 2020, 162 consecutive patients 
who required hospital admission with confirmed 
acute respiratory syndrome SarS-coV-2 infec-
tion via positive polymerase chain reaction test 
of nasopharyngeal swab sample and who showed 
severe arF (fraction of inspired oxygen [FiO2], 
arterial partial pressure of oxygen [PaO2] PaO2/
FiO2 ratio less than 250) due to pneumonia were 
included in the study.
exclusion criteria included requirement for 
rapid endotracheal intubation for cardiopulmo-
nary resuscitation, respiratory arrest, severe he-
modynamic instability, severe encephalopathy 
and more than two new extrapulmonary organ 
failures. Figure 1 shows study patients flow 
chart. Patients’ degree of severity and organ 
failure were estimated with Simplified Acute 
Physiology Score (SaPS) ii. Twenty-four of 162 
patients required immediate intubation and were 
admitted directly to icU.
on the experience gained in similar conditions.1-3 
In the first weeks of pandemic most patients were 
managed in intensive care units (icUs) with in-
vasive ventilation (iMV) as for other similar 
forms of arF. after an initial period of viral 
replication with fever and non-specific symp-
toms, typically five to ten days, a subsequent 
phase may follow in which excessive inflamma-
tory response produces diffuse alveolar damage, 
edema, endothelial damage with vascular throm-
bosis. in coronavirus disease 2019 (cOVid-19) 
ARF most often occurs within ten to fifteen days 
of initial viral invasion and may develop in just 
a few hours. early treatment may limit an ex-
aggerated inflammatory response. The careful 
selection of patients to treat with iMV as well 
as the very recent recognition that noninvasive 
ventilatory support (NiVS) (e.g. high flow na-
sal cannula [HFNc], continuous positive airway 
pressure [cPaP], noninvasive ventilation [NiV]) 
has an important role in therapy. a recent article 
demonstrated NiVS to be useful in patients with 
cOVid in arF cases.2 Patients with arF as a 
consequence of SarS-coV-2 typically show hy-
poxia, generally associated with respiratory al-
kalosis, a decreased paO2/FiO2 ratio values, and 
an increase in arterial alveolar O2-gradient (a-a 
dO2). The mechanisms of hypoxia are princi-
pally linked to alteration in the ventilation/perfu-
sion ratio with variable vascular shunt effect in 
the alveolar areas which are frequently excluded 
from ventilation.3
Very recently, the concept of phenotypes of 
hospitalized cOVid patients have suggested as 
guides to treatment.4, 5 Both protocols may be 
termed types of presentation. Both are based on 
computerized tomography (cT). each cautions 
the physician to be aware of thrombosis. Gatti-
noni et al. have hypothesized that cOVid-19 pa-
tients presents with the two different phenotypes: 
1) type L (low) presents with “diminished lung 
elastance, low ventilation to perfusion ratio,l 
ow lung weight and low lung recruitability (the 
amount of nonaerated lung tissue is low);” 2) 
type H (high) is characterized by “high pulmo-
nary elastance, high right to left shunt, high lung 
weight, and high lung recruitability.”4
in the L presentation, cT of the chest demon-
strates modest localized sub-pleural interstitial 
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The remaining 138 patients underwent a NiVS 
trial to avoid endotracheal intubation. all centers 
followed a clinical flow chart as described in 
previous studies on pandemics.7 Predetermined 
major criteria for admission to icU after NiVS 
included failure to maintain PaO2/FiO2<100 or 
development of conditions which require ur-
gent airway protection such as coma, failure to 
manage copious tracheal secretions, any hemo-
dynamic instability, inability to tolerate the in-
terface and/or inability to resolve dyspnea.7 a 
further criterion added to clinical flow was the 
distinction between L-type and H-type using 
cT evaluation.4, 5 A good interface fitting was 
guaranteed (24 hours/day) with timed checks by 
health-care workers. Moreover, every medical or 
health-care worker staff member wore a single-
layer respiratory PPe with gown, gloves, visor 
and fit-tested FFP3 mask.8 NiV was delivered 
using either icU ventilators or dedicated NiV 
platforms ventilators with double limb circuits. 
The most commonly used ventilation modes 
were pressure support ventilation (PSV), bi-
level positive airway pressure (Bi-PaP) and less 
often pressure control ventilation (PcV). When 
using the helmet, the titration of the ventilation 
was based upon what described by Vargas et al.9 
Figure 1.—Study flowchart. 
ricU: respiratory intermediate care unit; icU: intensive 
care unit; NiVS: Non-invasive ventilatory support; iMV: 
invasive mechanical ventilation (intubation); dNi: do not 
intubate order; cOVid: corona virus disease.
with an increase of 50% in both pressure support 
(PS)and positive end-expiratory pressure (PeeP) 
provided at the highest pressurization rate. The 
health care team consisted of infectious disease 
physicians, pulmonologists, experts on mechani-
cal ventilation, nurses, physiotherapists. a pul-
monologist with particular expertise in mechani-
cal ventilation was present in the units 12 hours 
per day and on call the other 12 hours. The nurse 
patient ratio was 1:3 to 1:4. it was possible to 
switch from NiVS to iMV at any moment. The 
therapeutic protocol included:
• antiviral drugs;
• hydroxychloroquine 200 mg bid for seven 
days;10
• corticosteroid therapy (dexamethasone 
6 mg/day or methylprednisolone 40-120 mg/
day);11, 12
• empiric antibiotics directed at community 
acquired pneumonia (e.g. ceftriaxone 2 gr iv/day 
plus azithromycin 500 mg iv/day);
• standard prophylactic coagulation with low 
molecular weight heparin. Therapeutic antico-
agulation was used in documented thromboem-
bolism;10
• tocilizumab 4-8 mg/kg in two administra-
tion in case of elevate interleukin-6 levels (iL-
6).11-13
The information for all patients, including de-
mographic data, medical comorbidities, clinical 
features, laboratory parameters, mode of respira-
tory support, level of PeeP, arterial blood gases 
analysis (aBG), PaO2/FiO2 ratio, the choice of 
interface were recorded. The number of patients 
who had died, had been discharged, length of hos-
pital stay, hospital and 28-day mortality were also 
noted. at admission patients had continuous mon-
itoring of electrocardiogram, arterial oxygen sat-
uration, blood pressure, respiratory rate (rr), and 
heart rate (Hr). The following parameters were 
recorded: age, sex, comorbidities, arterial blood 
gases (aBG), ventilation mode, and settings. 
ABG were withdrawn at a fixed interval after 1 -6 
hours, 24 hours from the beginning of NiVS and 
afterward at the discretion of the attending physi-
cian.7 The patients were divided in two groups: 
respiratory intensive care unit (ricU) admission 
and intensive care unit (icU) admission; results 
were compared between the two groups.
162 patients with severe acute respiratory 













38 patients NIVS 
failure (27.5%) 
12 admitted to ICU 
(IMV)
26 died (24 DNI)
138 patients (85.2%) 
admission to RICU 
and NIVS trial
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patients treated with NiVS 28 were treated with 
HFNc, 59 with cPaP delivered with oro-nasal 
mask or helmet (32 and 17 respectively), 51 with 
NiV delivered with oro-nasal or total face mask 
or helmet (22, 18 and 11 respectively).
Setting parameters according to respiratory 
support were the follows: HFNC flow 50.0±15.0, 
CPAP–PEEP 10.3±2.7 cm H2O and NiV–PeeP 
9.5±3.1 with pressure support (PS) 14.6±7.4 cm 
H2O.
Patients admitted to ICU were signifi-
cantly younger than those admitted to ricU 
(62.06±13.2 versus 70.98±14.75) and had more 
severe illness (SaPS ii and cUrB-65). More-
over, they had more severe respiratory impair-
ment than those admitted to ricU (PaO2 and 
PaO2/FiO2). Six of 162 patients (6.2%) had a 
do Not intubate orders (dNi) and were admit-
ted to ricU. Baseline characteristics of patients 
at admission are summarized in Table i. Most 
patients were male (64.4%). Hypertension, 
diabetes, obesity and cardiovascular disorders 
were the most frequent comorbidities. Obesity 
(BMi>30) were the most represented comorbid-
ity (56.9%).
One hundred patients were treated success-
fully with NiVS (72.5%); 38 failed NiVS trial 
(27.5%). The primary reason for NiVS failure 
was worsening of respiratory failure and ardS 
(eight patients), multi-organ failure (eight pa-
tients), severe cardiac injury (two patients), sep-
tic shock (two patients), and severe renal failure 
(one patient). among 38 NiVS failure twelve 
were intubated and admitted to icU, 6 were dNi 
Primary endpoints were NiVS failure and 
intubation rate, hospital mortality and 28-day 
mortality. Secondary outcomes were: hospital 
stay and factors related to NiVS failure and mor-
tality.
Statistical analysis
continuous data were expressed as means and 
standard deviation (Sd) and categorical vari-
ables as proportions. Logistic regression was 
used to evaluate univariate associations. Variable 
with P values <0.05 were included in the mul-
tivariate logistic regression mode with a condi-
tional stepwise model to correct for colinearity. 
Adjusted odds ratio and 95% confidence inter-
vals were associated with hospital mortality. a 
P value <0.05 was considered significant. Data 
analysis was made with SPSS statistics version 
25 software (iBM; armonk, NY, USa).
Results
One hundred sixty-two patients (92 males and 
56 females) 66.87±16.6 years old were admit-
ted to hospital because of severe arF due to 
cOVid-19 pneumonia. 24 patients (14.8%) un-
derwent immediate intubation and admission to 
icU. The primary reason for immediate intuba-
tion and icU admission was cardio-respiratory 
arrest (6 patients), septic or cardiac shock (4 
patients), rapid worsening respiratory failure (7 
patients) and multiorgan failure (MOF) (6 pa-
tients). One hundred thirty-eight patients were 
admitted to ricU for a NiVS trial. among the 
Table I.— Baseline characteristics of patients at admission.
Variable ricU (138 pts) icU (24 pts) P value
Sex (M%) 62.3% 66.6% 0.07
age (years) 70.98±14.75 62.06±13.21 0.002
SaPS ii score 26±8 34±6 0.01
cUrB 65 score 1±1 2±1 0.07
Past medical history
cardiovascular disorders 7 (5.0%) 4 (16.6%) 0.01
Hypertension 34 (24.65%) 7 (29.1%) 0.27
diabetes 16 (11.5%) 6 (25.0%) 0.03
respiratory disorders 4 (2.8%) 5 (20.8%) 0.001
Malignancy 4 (2.8%) 1 (4.1%) 0.12
chronic kidney diseases 3 (2,1%) 1 (4.1%) 0.44
Neurological disorders 4 (2.8%) 2 (8.3%) 0.04
Obesity 71 (51.45) 15 (62.5%) 0.06
immunosuppression treatment 2 (1.44%) 1 (4.1%) 0.04
 (To be continued) 
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Table I.— Baseline characteristics of patients at admission.
Variable ricU (138 pts) icU (24 pts) P value
Clinical findings
Fever 134 (97.15%) 23 (95.83%) 0.66
cough 67 (54.03%) 16 (66.6%) 0.03
dyspnea 128 (92.7%) 22 (91.66%) 0.59
chest pain 12 (8.69%) 3 (12.5%) 0.04
Syncope 2 (1.44) 3 (12.5) 0.003
Headache 13 (9.42%) 3 (12.5%) 0.07
Myalgia 104 (75.36%) 17 (70.83%) 0.09
diarrhea 10 (7.24%) 3 (12.5%) 0.05
Time from symptoms onset to hospital admission (days) 7.90±3.89 8.53±3.94 0.14
Time from symptoms onset to ventilatory support (days) 9.14±4.18 9.72±3.85 0.19
Laboratory values
red blood cells 106 u/L 4.20±0.752 4.21±0.721 0.26
White blood cells u/L 7783±4809 8399±4788 0.67
Lymphocytes cells u/L 927.07±588.12 695.00±528.22 0.02
Platelet 103 u/L 237.45±111.49 254.19±131.08 0.56
c-reactive protein mg/dL 9.64±9.34 11.99±10.99 0.11
Pro-calcitonin mcg/L 7.56±58.03 2,31±9.69 0.59
Ferritin mcg/L 851.3±1160.8 715.64±802.4 0.34
interleukin 6 pg/mL 13,81±31.23 32.76±57.77 0.009
aPTT ratio 33.88±4.88 35.72±6.78 0.13
PT % 92.22±17.74 90.33±18.49 0.44
aT iii % 94.39±35,33 94.28±15.23 0.46
Fibrinogen mg/dL 441.57±152.97 515.17±211.52 0.02
d-dimer ng/ml 4.71±8.03 3.86±7.41 0.25
creatinine kinase U/L 213.14±705.56 163.28±141.98 0.18
aST U/L 62.84±48.3 52.92±34.48 0.34
aLT U/L 46.49±39.29 63.03±60.25 0.22
Lipase U/L 75.54±60.07 52.22±46.90 0.23
BNP ng/L 145.95±74.44 254.44±74.33 0.02
Troponin ng/L 118.78±60.9 89.50±28.83 0.09
creatinine mg/dL 1.088±0.94 1.209±1.21 0.31
Sodium mmol/L 135.2±4.3 136.8±3.7 0.24
Potassium mmol/L 3.99±0.77 4.01±0.63 0.19
calcium mg/dL 7.8±1.1 7.7±1.4 0.33
Glucose mg/dL 114.6±12.8 123.4±23.6 0.10
LdH U/L 396.73±349.97 357.58±139.87 0.14
Radiological findings
Monolateral pneumonia 5 (3.62%) 1 (4.16%) 0.08
Bilateral pneumonia 133 (96.3%) 22 (91.6%) 0.21
Type L phenotype 128 (92.8%) 10 (41.75) 0.003
Type H phenotype 10 (7.2%) 14 (58.3%) 0.001
respiratory parameters
respiratory rate 31.92±1.94 33.14±2.30 0.02
Heart rate 95.78±4.79 105.86±8.42 0.01
paO2 mmHg 42.78±7.12 34.47±7.50 0.01
pacO2 mmHg 37.38±9.18 44.61±24.51 0.09
pH 7.46±0.53 7.41±0.51 0.04
satO2% 85.78±4.79 83.28±3.23 0.06
PaO2/FiO2 203.49±35.77 161.19±34.77 0.001
aadO2 mmHg 60.7±10.2 61.5±9.99 0.10
Lactate mmol/L 2.1±1.0 3.4±1.3 0.05
Variables are expressed as numerical and percentage values for dichotomic variables and mean and standard deviation (Sd) for continuous 
variables.
RICU: respiratory intermediate care unit; ICU: Intensive Care Unit; SAPS II: simplified acute physiology score; CURB 65: CURB-65 
score for pneumonia severity; aPTT: activated partial thromboplastin time; PT: prothrombin time; aT: antithrombin iii; aST: aspartate 
aminotransferase, aLT: alanine aminotransferase; BNP: brain-type natriuretic peptide; LdH: lactate dehydrogenase; paO2: arterial partial 
pressure of oxygen; pacO2: arterial partial pressure of carbon dioxide; satO2: arterial oxygen saturation; paO2/FiO2: arterial partial pressure 
of oxygen fraction concentration of oxygen in inspired air ratio; aadO2: alveolar-arterial oxygen gradient; rr: respiratory rate (breaths/min); 
Hr: heart rate (beats/min).
 (continues).
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Discussion
This study demonstrated that NiVS was effec-
tive in reducing intubation rate and mortality. To 
our knowledge only a few previous studies have 
explored the use of NiVS in severe arF due to 
cOVid -19 related pneumonia outside icU.15-17
The first study of NIV in a cohort of 1305 pa-
tients together with mortality predictors. NiV 
was used in 21.1% of patients and iMV in 24.9%. 
age greater than 60 years and increasing number 
of comorbidities were independent predictors of 
in-hospital mortality.15 in another study reported 
a little cohort (fifteen patients) treated with NIV 
(associated with prone position) in mild to mod-
erate ardS. all patients showed a reduction of 
rr and improvement PaO2/FiO2 ratio. among 
them, thirteen improved, one was intubated, 
and one died.16 The latter is an observational 
study including 670 patients with arF due cO-
Vid-19 related pneumonia. The authors noted 
an intubation rate of 27% and 30-day mortality 
of 26.9%. Mortality rate increased with age and 
comorbidities.17 Two further studies included 38 
and 30 patients were carried out in two respira-
tory and emergency wards. The authors have 
reported a hospital mortality 50% and 26.7% re-
spectively. Mortality was associated with higher 
PeeP.18, 19 Our data are in accord with those re-
ported previously: we have observed NiVS fail-
ure was 27.5% and hospital mortality 23.18%. 
it is interesting to observe that these results did 
order and 20 died without an expressed writ-
ten dNi order and were not intubated after an 
evaluation of a multidisciplinary team in which 
included pulmonologists, intensivists, and anes-
thesiologists along with experts in medical eth-
ics were involved.14
in hospital mortality was 23.18% in ricU 
group and 30.55% in icU group, but mortality 
in patients admitted immediately to icU was 
20.83%. Overall, 28-day mortality was 30.70%; 
90-day mortality was 33.2%.
Patients with NiVS failure were older than 
those in whom NiVS succeeded. a lower num-
ber of lymphocytes, a higher iL-6 (P<0.001) 
as well as lower PaO2, PacO2, PaO2/FiO2 ratio 
higher respiratory rate (rr) and heart rate (Hr) 
at admission (P<0.001 and 0.002). Furthermore, 
NiVS failure were associated with lower PaO2 
and PaO2/FiO2 ratio and higher rr after 1-6 
hours. Variables associated to NiVS failure are 
reported in Table ii.
Hospital survivors was younger, had a shorter 
hospital stay and lower d-dimer, c-reactive pro-
tein, troponin, ferritin, LdH, cPK at admission 
as well as lower SaPS-ii on initial evaluation. 
Moreover, they presented with higher PaO2 and 
PaO2/FiO2 at admission as well as a higher PaO2/
FiO2 ratio and lower rr after 1-6 h (Table iii). 
Multivariate analysis identified higher age, C-re-
active protein, rr after 1-6 hours and PaO2/FiO2 
ratio after 1-6 hours as an independent predictor 
of hospital mortality (Table iV).
Table II.— Variable associated with failure of NIVS.
Variable Survivors(106 pts)
Not survivors
(32 pts) P value
age 62.1±13.2 71.6±14.8 0.001
Lymphocytes 695.0±528.9 953.5±599.2 0.03
iL-6 pg/mL 28.1±22.26 63.9±50.78 0.001
PaO2 at admission 43.4±6.7 36.6±7.5 0.001
PacO2 at admission 44.6±4.5 37.0±7.8 0.001
paO2/FiO2 ratio at admission 174.2±36.2 161.1±34.7 0.0001
rr at admission 31.7±1.8 33.1±2.3 0.02
Hr at admission 100.7±7.7 109.00±4.1 0.007
PaO2 after 1-6 h 106.0±20.4 89.7±7.4 0.001
PaO2/FiO2 after 1-6 h 251.2±61.3 186.7±43.5 0.002
rr after 1-6 h 26.3±4.0 31.4±3.6 0.019
Variables are expressed as mean and standard deviation (Sd).
NiVS: noninvasive ventilatory support; iL -6: interleukin 6; paO2: arterial partial pressure of oxygen; pacO2: arterial partial pressure of carbon 
dioxide; paO2/FiO2: arterial partial pressure of oxygen/fraction concentration of oxygen in inspired air ratio; rr: respiratory rate (breaths/min);
Hr: heart rate (beats/min).
COPYRIGHT© 2021 EDIZIONI MINERVA MEDICA
SarS-cOV-2 PNeUMONia WiTH NONiNVaSiVe VeNTiLaTOrY SUPPOrT diaZ de TeraN
Vol. 112 - No. 3 MiNerVa Medica 335
mission. A final consideration regards the criteria 
suggested to evaluate the plausible phase of the 
disease: we have used it and took into consider-
ation the different location and instrumentation 
in the therapy of arF.26 in patients with cT and 
or lung ultrasound patterns suggesting a L-phe-
notype a NiVS trial with low-moderate PeeP 
and low tidal volumes to redistribute pulmonary 
blood flow from damaged to normal lung areas 
was started. When a H-phenotype (ardS-like 
pattern) was diagnosed predominant high PeeP 
and prone position was employed; these patients 
were most often treated in the icU.4, 5, 26 These 
radiological criteria should be used in concert 
with the epidemiological, clinical and labora-
tory severity of patient’s illness to determine the 
better ventilation choice for that patient.27-31 in a 
recently published study demoule et al. studied 
379 cOVid-19 patients admitted to four icUs; 
these investigators found a significant reduction 
of iMV and a similar 28-day mortality compared 
to patients intubated from the beginning. The au-
thors explain this observation: SarS-coV-2 in-
fection does not coincide with the typical courses 
or features of ardS.32
Limitations of the study
This study has some limitations. The retrospec-
tive design does not permit definitive conclu-
sions about the effectiveness of NiVS. Second, 
not differ from some important and larger stud-
ies made in icU (from 21% to 24.5%).20, 21 also, 
predictors of failure were similar to previous 
studies.15, 20-23 Protection of health care worker 
should be another significant aspect in COVID 
pandemic management. For this reason, person-
al protective equipment and negative pressure 
rooms or at least rooms with natural ventilation 
should be employed.19 Following all the sug-
gested precautions and protection some studies 
reported an infection rate tested via pharyn-
geal swab or serology in health workers about 
10%.19, 24 in our units a protocol similar to the 
protocol in Wuhan study was implemented.25 
FFP3 masks available for all operators. Further-
more, aerosol mode was not used to administer 
respiratory drugs. By following strictly, a devel-
oped protocol for cOVid-19 intensive care only 
seven of 112 health workers (6.25%) developed 
cOVid-19, but only two required hospital ad-
Table III.— Variables associated with mortality.
Variable Survivors(125 pts)
Not survivors
(37 pts) P value
age 66.0±10.0 69.1±3.8 0.0001
d-dimer mg/L 4.5±2.6 7.8±2.5 0.001
Lymphocytes cells/mm3 658.6±502.7 967.9±448.3 0.002
crP mg/dL 8.7±8.5 13.5±6.3 0.002
Ferritin mcg/L 631.89±343.7 1297.7±589.6 0.016
Troponin ng/L 34.7±19.4 308.12±91.0 0.004
LdH U/L 312.±142.3 576.6±188.5 0.001
BNP pg/mL 88.6±78.18 646.1±370.8 0.001
cK U/L 148.6±119.8 1136.5±408.5 0.001
PaO2 at admission 42.2±3.6 38.0±8.2 0.001
PaO2/FiO2 ratio at admission 200.9±37.3 179.2±11.5 0.001
PaO2 /FiO2 after 1-6 h 200.9±37.3 179.21±25.4 0.001
rr after 1-6 hours 24.4±3.6 32.0±3.2 0.001
Hospital stay 17.0±4.7 22.5±4.7 0.002
Variables are expressed as mean and standard deviation (SD). Statistical significance was set for P<0.05.
crP: c-reactive protein; LdH: lactate dehydrogenase; BNP: brain-type natriuretic peptide;
cK creatine phosphokinase; PaO2: arterial partial pressure of oxygen; PaO2/FiO2: arterial partial pressure of oxygen/fraction concentration of 
oxygen in inspired air ratio; rr: respiratory rate (breaths/min).
Table IV.— Multivariate analysis of variables inde-
pendently associated with hospital mortality.
Variable Or 95% ci P value
age 1.09 1.04-1.14 0.0001
crP 1.08 1.01-1.15 0.016
PaO2/FiO2 after 1-6 h 0.97 0.96-0.98 0.02
rr after 1-6 h 1.39 1.04-1.85 0.0001
crP: c reactive protein; paO2/FiO2: arterial partial pressure of 
oxygen/fraction concentration of oxygen in inspired air ratio; rr: 
respiratory rate (breaths/min).
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19-related pneumonia. eur respir J 2020;56:2002130. 
18. Burns GP, Lane Nd, Tedd HM, deutsch e, douglas F, 
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invasive pressure support for severe hypoxia in a cohort of 
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UK teaching hospital. BMJ Open respir res 2020;7:e000621. 
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L, carpinteri G. cOVid-19: a single experience in intermedi-
ate care Unit. ital J emerg Med 2020;9:131–6. 
20. Grasselli G, Zangrillo a, Zanella a, antonelli M, cabrini 
L, castelli a, et al.; cOVid-19 Lombardy icU Network. 
Baseline characteristics and Outcomes of 1591 Patients in-
fected With SarS-coV-2 admitted to icUs of the Lombardy 
region, italy. JaMa 2020;323:1574–81. 
21. richardson S, Hirsch JS, Narasimhan M, crawford 
JM, McGinn T, davidson KW, et al.; the Northwell cO-
Vid-19 research consortium. Presenting characteristics, 
comorbidities, and Outcomes among 5700 Patients Hospi-
talized With cOVid-19 in the New York city area. JaMa 
2020;323:2052–9. 
22. du rH, Liang Lr, Yang cQ, Wang W, cao TZ, Li M, et 
al. Predictors of mortality for patients with cOVid-19 pneu-
monia caused by SarS-coV-2: a prospective cohort study. 
eur respir J 2020;55:2000524. 
23. Martins-Filho Pr, Tavares cS, Santos VS. Factors asso-
ciated with mortality in patients with cOVid-19. a quantita-
tive evidence synthesis of clinical and laboratory data. eur J 
intern Med 2020;76:97–9. 
24. duca a, Oppedisano i, Zanardi F, rosti V, cosentini 
r. cOVid-19.The Bergamo viral earthquake. ital J emerg 
2020;9:102–5.
25. Meng L, Qiu H, Wan L, ai Y, Xue Z, Guo Q, et al. intuba-
the decision to start NiVS modes was left to the 
attending physician and not always discussed by 
a multidisciplinary team. The critical nature of 
the situation did not always permit a shared de-
cision. change in treatment strategy was always 
an option.
Conclusions
in summary, severe and critical cOVid-19 pa-
tients are a challenge for intensivists. From the 
beginning of pandemic patients with severe arF 
were treated with NiVS. Our experience with 
severe cOVid-19 admitted to our ricUs can 
help and encourage clinicians to consider the 
possibility of using NiVS in selected patients. 
This option has shown a favorable rate of suc-
cess manifested by an apparent improvement in 
mortality and reduced the length of hospital stay 
in the carefully selected patient.
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